Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tenaya Therapeutics, Inc.

TNYA Clue Score23
United States Fiscal year ends December CIK 0001858848 Results filed 4 Nov 2026

What the insiders did Net buying

By person

12 insiders · 96 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
David Goeddel V
Director
$64.56M (8)
—
+$64.56M
54,299,129
$38.54M
—
Column Group III Gp, LP entity
10% owner
$64.56M (8)
$5.93M (12)
+$58.63M
4,985,570
$3.54M
—
Eli Casdin
Director
$19.23M (2)
—
+$19.23M
6,440,829
$4.57M
+1,679%
Casdin Partners Master Fund, L.P. entity
10% owner
$12.75M (1)
—
+$12.75M
361,969
$256.93K
—
Deepak Srivastava
Director
$600.00K (1)
—
+$600.00K
372,435
$264.35K
+162.9%
Timothy Hoey
Chief Scientific Officer
—
$145.41K (7) scheduled
−$145.41K
245,346
$174.15K
+22.7%
Faraz Ali
Chief Executive Officer
—
$143.72K (19)
−$143.72K
539,782
$383.14K
—
Whittemore Tingley
Chief Medical Officer
—
$107.29K (20)
−$107.29K
263,073
$186.73K
+719.3%
Leone D Patterson
Chief Fin. and Bus. Officer
—
$47.44K (2)
−$47.44K
95,755
$67.97K
+1,671%
Chihiro Saito
SVP, Accounting and Fin. Ops.
—
$11.63K (4)
−$11.63K
60,983
$43.29K
+50.2%
Tomohiro Higa
SVP, Finance
—
$10.89K (12)
−$10.89K
118,267
$83.95K
+15.8%
JeenJoo Kang
Director
—
—
—
25,000
$17.75K
+100.0%

No percentages here. This company's share count has moved by a factor of 2.6 over the window, from 87,582,646 to 224,230,012 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.